In searching for an optimal induction regimen , we conducted two separate randomized trials of 38 living donor and 90 deceased donor adult , primary kidney transplant recipients comparing antithymocyte globulin ( Thymoglobulin ) ( group A , N = 43 ) versus alemtuzumab ( group B , N = 43 ) versus daclizumab ( group C , N = 42 ) , using exactly the same three treatment arms in each trial .